CHOP researchers have shown that adenovirus proteins use a process called phase separation to coordinate production of viral progeny, which could have broad implications.

Levy traveled from Brazil and participated in a clinical trial for an oral drug that targets an NTRK gene fusion that drives cancer-cell growth.

With support from Jazz Pharmaceuticals, the grant will fund a SU2C Catalyst® Research Team led by Dr. Grohar; the team will investigate new, targeted treatments for patients 10 years and older with Ewing sarcoma.

CHOP researchers have developed a custom-built application to automate determination of engraftment, a key outcome after hematopoietic stem cell transplant.

Through collaboration with research partners, patients, foundations, and community members, we are working to defeat childhood brain cancer and find better treatments for current patients. Read about recent milestones we’ve hit to accelerate pediatric brain tumor research.

Read this case study about integrating precision medicine into the standard of care for children with thyroid cancer.

Nearly 50 faculty, staff and trainees from the Division of Hematology and Division of Oncology at Children’s Hospital of Philadelphia attended the 64th Annual American Hematology Society (ASH) Meeting in New Orleans, Louisiana.

Two researchers from Children’s Hospital of Philadelphia (CHOP) were recently selected by the health and science news outlet STAT as 2022 Wunderkinds, an award that celebrates the next generation of scientific superstars who are making significant contributions to biomedical research.

A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.

CHOP researchers found that a series of “liquid biopsies” could less invasively and more accurately identify tumor changes in patients with high-risk neuroblastoma.